Modulation of tumor-associated lymphangiogenesis by combination immunotherapy approaches in triple-negative breast cancer: a systematic review
Triple-negative breast cancer's lymphatic immune system is underexplored for combination therapy, representing a significant research opportunity.
A systematic review of 59 studies identifies a significant gap: while tumor-associated lymphangiogenesis plays a dual role in TNBC metastasis and immune regulation, anti-lymphangiogenic agents are rarely combined with immunotherapy. This review maps the biological rationale and calls for development of novel combination strategies targeting TNBC's lymphatic immune axis.
What the study was
- Study design
- Systematic review (59 eligible articles)
- Population
- TNBC patients and preclinical TNBC models
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Frontiers in Immunology
Why it surfaced
Systematic review identifying unexplored combination immunotherapy strategy in TNBC; novel mechanistic angle on immune evasion in aggressive breast cancer.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.